Tyrosine kinase mutations in human cancer
- PMID: 17311534
- DOI: 10.2174/156652407779940486
Tyrosine kinase mutations in human cancer
Abstract
A subset of tyrosine kinases are activated by mutations which contribute to the malignant transformation, growth, and metastasis of human cancers. Mutations change the expression, conformation and/or stability of tyrosine kinases, often leading to constitutive activation of the signaling pathways the kinases regulate. Given that tyrosine kinases are key members of signaling cascades, mutations have multiple effects on various cellular proteins. This review will focus on four kinases (EGFR, c-Met, c-Kit, and PI3-kinase) known to be mutated in human cancer. It will discuss the effects that these mutations have on the biology of tumors, and how our understanding of the structure and function of kinases and their mutations is currently being used to design targeted treatments.
Similar articles
-
Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.J BUON. 2017 Jul-Aug;22(4):1053-1060. J BUON. 2017. PMID: 28952227
-
Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.Oncogene. 1998 Aug 13;17(6):741-9. doi: 10.1038/sj.onc.1201994. Oncogene. 1998. PMID: 9715276
-
Oncogene alterations in endometrial carcinosarcomas.Hum Pathol. 2013 May;44(5):852-9. doi: 10.1016/j.humpath.2012.07.027. Epub 2012 Nov 28. Hum Pathol. 2013. PMID: 23199529
-
[Tyrosine kinases in etiopathogenesis and therapy of malignant diseases--C-kit activating mutations].Med Pregl. 2010 May-Jun;63(5-6):380-6. doi: 10.2298/mpns1006380s. Med Pregl. 2010. PMID: 21186551 Review. Serbian.
-
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.Pharmacol Ther. 2018 Nov;191:123-134. doi: 10.1016/j.pharmthera.2018.06.016. Epub 2018 Jun 30. Pharmacol Ther. 2018. PMID: 29964125 Review.
Cited by
-
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia.Leuk Res. 2008 May;32(5):761-70. doi: 10.1016/j.leukres.2007.08.023. Epub 2007 Oct 18. Leuk Res. 2008. PMID: 17949810 Free PMC article.
-
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.Thyroid. 2010 Jul;20(7):697-706. doi: 10.1089/thy.2010.1646. Thyroid. 2010. PMID: 20578891 Free PMC article. Review.
-
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.Neoplasia. 2010 Jan;12(1):1-10. doi: 10.1593/neo.09948. Neoplasia. 2010. PMID: 20072648 Free PMC article.
-
Identification of Novel Gene Signature Predicting Lymph Node Metastasis in Papillary Thyroid Cancer via Bioinformatics Analysis and in vitro Validation.Int J Gen Med. 2025 Mar 15;18:1463-1479. doi: 10.2147/IJGM.S502480. eCollection 2025. Int J Gen Med. 2025. PMID: 40110574 Free PMC article.
-
The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer.Curr Signal Transduct Ther. 2011;6(2):146-151. doi: 10.2174/157436211795659955. Curr Signal Transduct Ther. 2011. PMID: 25197268 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous